Researchers at The Ohio State University Comprehensive Cancer Center have conducted the first clinical trial of a new targeted drug, nemtabrutinib, in humans.
This drug offers a promising treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) who no longer respond to standard treatments.
Challenges in Blood Cancer Treatment
While several drugs are available for treating B-cell cancers, many patients initially respond to these treatments but eventually experience disease progression.
Relapsed blood cancers can be challenging to treat, and some patients exhaust standard treatment options. This clinical trial investigated nemtabrutinib as a potential solution for patients facing progressive blood cancers after previous treatments.
How Nemtabrutinib Works
Blood cancers often involve B-cells, which, instead of fighting infections, begin to divide uncontrollably, leading to cancer.
Existing drugs for B-cell cancers target Bruton’s tyrosine kinase (BTK), a key enzyme involved in this process. These drugs block the enzyme’s action, causing abnormal B-cells to die.
However, many patients experience temporary effects, as the BTK enzyme mutates over time, rendering existing drugs ineffective.
Nemtabrutinib was designed to overcome this challenge by binding to BTK even in the presence of common mutations. Additionally, it binds to other essential proteins in B-cell cancers.
Study Methods and Results
The researchers conducted the clinical trial with 47 patients who had undergone at least two prior therapies for their blood cancer. Over half of these patients had relapsed CLL, while others had NHL.
Patients received daily doses of nemtabrutinib, with varying dosages throughout the trial. Researchers monitored their responses to the drug and side effects.
The results were highly promising:
- More than 75% of patients with relapsed CLL responded to the drug, even those with BTK mutations.
- Most patients remained cancer-free for at least 16 months during the trial.
- While patients experienced some side effects, many were minor and manageable, confirming the drug’s safety.
Next Steps
Nemtabrutinib is progressing to larger and more definitive trials. It will be evaluated against standard-of-care drugs and in combination with other active medications.
The drug’s potential to provide effective and safe treatment for blood cancers could significantly impact patients’ lives.
Conclusion
Blood cancers, including CLL and NHL, pose significant challenges in treatment. However, the emergence of nemtabrutinib as a targeted drug shows promise in addressing these challenges.
By effectively targeting B-cell cancers, including those with BTK mutations, and demonstrating safety in clinical trials, nemtabrutinib offers hope for patients who have exhausted standard treatment options.
Further research and trials will provide more insights into the drug’s effectiveness, potentially transforming the landscape of blood cancer treatment.
If you care about cancer, please read studies that artificial sweeteners are linked to higher cancer risk, and how drinking milk affects risks of heart disease and cancer.
For more information about health, please see recent studies about the best time to take vitamins to prevent heart disease, and results showing vitamin D supplements strongly reduces cancer death.
The research findings can be found in Cancer Discovery.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
